EMulate -Mensana Therapeutics
Mensana is feasibility (phase I) trial ready for treatment of PTSD, depression, anxiety and addiction by the application of specific psychoactive ulRFE fields, another expression of EMulate’s Therapeutic technology.
Most popular related searches
medical device
patient handling
therapeutic benefit
depression
anxiety depression
anxiety
post-traumatic stress disorder
- ulRFE fields are not controlled substances
- Shorter duration of effect than actual psychoactive compounds
- Patient can turn off the medical device if in distress; wears off quickly
- MD prescribes, therapists can administer independently
- Most psychedelic drugs have no composition of matter protection. The use of ulRFE fields is eligible for utility patent protections.